RhumbLine Advisers
KMTS

RhumbLine Advisers’s Kestra Medical Technologies KMTS Stock Holding History

RhumbLine Advisers’s Portfolio KMTS Stock Details KMTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$525K Buy
26,338
+10,584
+67% +$249K ﹤0.01% 2581
2025
Q4 		$418K Buy
15,754
+2,829
+22% +$72.9K ﹤0.01% 2781
2025
Q3 		$307K Buy
12,925
+874
+7% +$15.6K ﹤0.01% 2979
2025
Q2 		$200K Buy
+12,051
New +$263K ﹤0.01% 3229

Other funds holding KMTS

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AP
Andera Partners Paris $177M AUM
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RhumbLine Advisers's KMTS Position: Q1 2026 in Review

RhumbLine Advisers increased its Kestra Medical Technologies (KMTS) stake by 67% in Q1 2026, buying an estimated $249K and bringing the position to 26,338 shares worth $525K. The position accounts for ﹤0.01% of the portfolio, ranked #2581.

RhumbLine Advisers first reported a position in KMTS in Q2 2025 and has held it in 4 quarters since. 103 funds tracked by Wall St. Rank hold KMTS as of Q1 2026.

  • RhumbLine Advisers held 26,338 shares of Kestra Medical Technologies worth $525K as of Q1 2026.
  • RhumbLine Advisers bought 10,584 Kestra Medical Technologies shares in Q1 2026, an estimated $249K.
  • Kestra Medical Technologies made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2581 holding.
  • RhumbLine Advisers first reported a position in Kestra Medical Technologies in Q2 2025 and has held it in 4 quarters since.
  • 103 funds tracked by Wall St. Rank held Kestra Medical Technologies as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.